Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

NCT03620955 · clinicaltrials.gov ↗

UNKNOWN

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Risk-directed Therapy
Cytogenetic Abnormality
Molecular Abnormality
MRD

Interventions

OTHER: Justified risk stratification based on MRD after three course chemo therapy

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]